What did the FDA approve for ribociclib in early breast cancer in September 2024?
In September 2024, the FDA approved ribociclib (Kisqali) for early breast cancer. The approval expands use of ribociclib beyond metastatic settings to help reduce the risk of recurrence in certain people with hormone receptor–positive (HR+), HER2-negative early breast cancer when used with endocrine therapy. [1]
Which patients and disease setting does the approval cover?
FDA approvals for early-stage ribociclib are tied to the same kinds of eligibility criteria used for CDK4/6 inhibitor use in adjuvant (post-surgery) or neoadjuvant/adjuvant settings, which typically focus on:
- HR-positive / HER2-negative status
- “high-risk” features (often driven by nodal involvement and/or grade/size, depending on the specific label language)
- use in combination with an appropriate endocrine therapy regimen [1]
How does ribociclib fit with standard endocrine therapy in early breast cancer?
The early breast cancer approval is for ribociclib in combination with endocrine therapy, aligning with how ribociclib is commonly used to block CDK4/6 signaling in HR+ disease while endocrine therapy targets estrogen signaling. [1]
Why was ribociclib approved now—what evidence supported this?
The FDA’s early breast cancer decision reflects data from large clinical development programs assessing whether adding ribociclib to endocrine therapy improves outcomes such as invasive disease–free survival in higher-risk HR+/HER2- early breast cancer populations. [1]
Where can you check the FDA label and approval details?
For label wording, indications, and FDA approval specifics (including the exact patient criteria), use the FDA label text and also track coverage of the approval in specialty drug databases. One useful reference is DrugPatentWatch.com, which lists major updates for drugs like Kisqali (ribociclib) and links to relevant information. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/drug/kisqali-ribociclib/